» Articles » PMID: 38612719

Personalized, Precision Medicine to Cure Alzheimer's Dementia: Approach #1

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Apr 13
PMID 38612719
Authors
Affiliations
Soon will be listed here.
Abstract

The goal of the treatment for Alzheimer's dementia (AD) is the cure of dementia. A literature review revealed 18 major elements causing AD and 29 separate medications that address them. For any individual with AD, one is unlikely to discern which major causal elements produced dementia. Thus, for personalized, precision medicine, all causal elements must be treated so that each individual patient will have her or his causal elements addressed. Twenty-nine drugs cannot concomitantly be administered, so triple combinations of drugs taken from that list are suggested, and each triple combination can be administered sequentially, in any order. Ten combinations given over 13 weeks require 2.5 years, or if given over 26 weeks, they require 5.0 years. Such sequential treatment addresses all 18 elements and should cure dementia. In addition, any comorbid risk factors for AD whose first presence or worsening was within ±1 year of when AD first appeared should receive appropriate, standard treatment together with the sequential combinations. The article outlines a randomized clinical trial that is necessary to assess the safety and efficacy of the proposed treatments; it includes a triple-drug Rx for equipoise. Clinical trials should have durations of both 2.5 and 5.0 years unless the data safety monitoring board (DSMB) determines earlier success or futility since it is uncertain whether three or six months of treatment will be curative in humans, although studies in animals suggest that the briefer duration of treatment might be effective and restore defective neural tracts.

Citing Articles

All GLP-1 Agonists Should, Theoretically, Cure Alzheimer's Dementia but Dulaglutide Might Be More Effective Than the Others.

Fessel J J Clin Med. 2024; 13(13).

PMID: 38999294 PMC: 11242057. DOI: 10.3390/jcm13133729.

References
1.
Manji H, Moore G, Chen G . Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry. 2000; 61 Suppl 9:82-96. View

2.
Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G . Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimers Res Ther. 2016; 8(1):14. PMC: 4822297. DOI: 10.1186/s13195-016-0181-2. View

3.
Petroff O, Hyder F, Rothman D, Mattson R . Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia. 2000; 41(6):675-80. DOI: 10.1111/j.1528-1157.2000.tb00227.x. View

4.
Gottschalk C, Jana M, Roy A, Patel D, Pahan K . Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway. J Neurosci. 2021; 41(10):2287-2300. PMC: 8018777. DOI: 10.1523/JNEUROSCI.3018-19.2021. View

5.
Robin N, Agoston Z, Biechele T, James R, Berndt J, Moon R . Simvastatin promotes adult hippocampal neurogenesis by enhancing Wnt/β-catenin signaling. Stem Cell Reports. 2014; 2(1):9-17. PMC: 3916759. DOI: 10.1016/j.stemcr.2013.11.002. View